2026 Global: Cardiovascular Genetic Testing Market-Competitive Review (2032) report
Description
The 2026 Global: Cardiovascular Genetic Testing Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiovascular genetic testing market by geography and historical trend. The scope of the report extends to sizing of the cardiovascular genetic testing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Qiagen, Bio-Rad Laboratories Inc., Danaher, Myriad Genetics, Inc., Natera, Inc., Abbott, and Laboratory Corporation of America Holdings dominate the Cardiovascular Genetic Testing Market. These ten companies lead through innovations in next-generation sequencing (NGS), polygenic risk scores (PRS), and comprehensive panels for conditions like familial hypercholesterolemia, long QT syndrome, and cardiomyopathies. Illumina excels in DNA sequencing and array technologies, powering whole-genome sequencing (WGS) for rapid detection of heart disease variants and serving as a founding member of the CardioGenomic Testing Alliance (CGTA). Thermo Fisher Scientific advances high-throughput testing with acquisitions like Olink for proteomics integration, enhancing multiplexed protein analysis alongside genetic assays. F. Hoffmann-La Roche Ltd. and its Genentech subsidiary innovate in molecular diagnostics, contributing to panel tests and genome-wide association studies amid rising CVD prevalence.
Danaher and Bio-Rad Laboratories drive market growth via precision tools for genetic risk assessment. Danaher's portfolio supports scalable genetic analysis, while Bio-Rad focuses on laboratory solutions for accurate variant detection in cardiovascular disorders. Myriad Genetics specializes in hereditary panels for inherited cardiac conditions, partnering with healthcare systems for broader adoption. Natera leverages cell-free DNA testing for organ health, including cardiology applications, backed by over 300 peer-reviewed studies. Abbott expands through biomarker integration, reducing costs and improving accessibility for single-gene and panel tests. Laboratory Corporation of America Holdings (Labcorp), now with Invitae, enhances nationwide access via patient service centers and comprehensive genomic profiling.
These leaders navigate a market projected to grow from USD 9.07 billion in 2023 at 11.20% CAGR to USD 19.07 billion by 2031, fueled by personalized medicine and AI-driven algorithms. North America leads due to advanced infrastructure, with Europe and Asia-Pacific following via NHS partnerships and rising healthcare investments. Innovations like GENinCode's (noted in alliances) polygenic tools underscore competitive edges, though smaller players like PerkinElmer and PacBio contribute niche advancements. Overall, these firms prioritize FDA-approved tests, cost reductions, and collaborations to address CVD as the top global killer, enabling preventive strategies through monogenic and polygenic insights.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiovascular genetic testing market by geography and historical trend. The scope of the report extends to sizing of the cardiovascular genetic testing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Qiagen, Bio-Rad Laboratories Inc., Danaher, Myriad Genetics, Inc., Natera, Inc., Abbott, and Laboratory Corporation of America Holdings dominate the Cardiovascular Genetic Testing Market. These ten companies lead through innovations in next-generation sequencing (NGS), polygenic risk scores (PRS), and comprehensive panels for conditions like familial hypercholesterolemia, long QT syndrome, and cardiomyopathies. Illumina excels in DNA sequencing and array technologies, powering whole-genome sequencing (WGS) for rapid detection of heart disease variants and serving as a founding member of the CardioGenomic Testing Alliance (CGTA). Thermo Fisher Scientific advances high-throughput testing with acquisitions like Olink for proteomics integration, enhancing multiplexed protein analysis alongside genetic assays. F. Hoffmann-La Roche Ltd. and its Genentech subsidiary innovate in molecular diagnostics, contributing to panel tests and genome-wide association studies amid rising CVD prevalence.
Danaher and Bio-Rad Laboratories drive market growth via precision tools for genetic risk assessment. Danaher's portfolio supports scalable genetic analysis, while Bio-Rad focuses on laboratory solutions for accurate variant detection in cardiovascular disorders. Myriad Genetics specializes in hereditary panels for inherited cardiac conditions, partnering with healthcare systems for broader adoption. Natera leverages cell-free DNA testing for organ health, including cardiology applications, backed by over 300 peer-reviewed studies. Abbott expands through biomarker integration, reducing costs and improving accessibility for single-gene and panel tests. Laboratory Corporation of America Holdings (Labcorp), now with Invitae, enhances nationwide access via patient service centers and comprehensive genomic profiling.
These leaders navigate a market projected to grow from USD 9.07 billion in 2023 at 11.20% CAGR to USD 19.07 billion by 2031, fueled by personalized medicine and AI-driven algorithms. North America leads due to advanced infrastructure, with Europe and Asia-Pacific following via NHS partnerships and rising healthcare investments. Innovations like GENinCode's (noted in alliances) polygenic tools underscore competitive edges, though smaller players like PerkinElmer and PacBio contribute niche advancements. Overall, these firms prioritize FDA-approved tests, cost reductions, and collaborations to address CVD as the top global killer, enabling preventive strategies through monogenic and polygenic insights.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.